Physician profile
John Ryan Cunningham
NPI 1578686507
$13,409.42
in general payments reported to CMS, 2019-2025
35 companies · $2,851 in 2025
The $2,851 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $291 · 2021: $1,840 · 2022: $2,418 · 2023: $2,298 · 2024: $2,661 · 2025: $2,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,667 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,667.17 |
| Education | $143.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,117.05 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,125.48 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,418.88 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $826.08 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ferring Pharmaceuticals INC. | $729.62 | 2019-2023 | Rebyota |
| Celgene Corporation | $577.56 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $500.93 | 2023-2025 | Voquezna |
| Pfizer INC. | $447.79 | 2019-2025 | |
| Madrigal Pharmaceuticals | $332.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $279.15 | 2022-2025 | |
| Redhill Biopharma INC. | $276.57 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Qol Medical, LLC | $243.38 | 2019-2025 | Sucraid, Sucraid |
| Anx Robotica Corp | $238.66 | 2025 | |
| Evoke Pharma, INC. | $218.41 | 2021-2024 | |
| Intercept Pharmaceuticals, INC. | $210.67 | 2021-2023 | Ocaliva |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $191.67 | 2019 | |
| Lilly USA, LLC | $179.75 | 2023-2025 | Omvoh |
| Olympus America INC. | $167.59 | 2023-2025 | Single Use Repositionable Clip, Disposable Biopsy Forceps, Evis Exera Lll Colonovideoscope |
| Ardelyx, INC. | $166.85 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $147.71 | 2024 | Resolution Clip, Resolution 360 Clip |
| Gilead Sciences, INC. | $134.47 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $115.80 | 2021-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $108.55 | 2019-2024 | |
| Celltrion USA INC. | $103.98 | 2023-2025 | Yuflyma, Zymfentra, Vegzelma |
| Aimmune Therapeutics, INC. | $99.37 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $98.30 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $87.26 | 2024 | Iqirvo, Bylvay |
| Braintree Laboratories, INC. | $82.70 | 2019-2025 | Sutab, Suflave |
| Ucb, INC. | $53.75 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $36.20 | 2025 | Dupixent |
| Daiichi Sankyo INC. | $32.83 | 2019-2020 | |
| Medtronic, INC. | $23.49 | 2025 | Gi Genius |
| Azurity Pharmaceuticals, INC. | $20.74 | 2025 | Suflave |
| Dova Pharmaceuticals | $15.61 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$83,024.46 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.